Our findings suggest that HPV+ cervical cancer cells display greater resistance to cisplatin compared to HPV-cells, whilst an increased sensitivity to EZH2 inhibitor EPZ6438 was indicated in vitro. This evidence concerns the gene EZH2 and cervical cancer.